Physician profile
Brian Butcher
NPI 1003831629
$2,942.52
in general payments reported to CMS, 2019-2025
27 companies · $478 in 2025
The $478 reported for 2025 was more than what 85% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $358 · 2021: $450 · 2022: $427 · 2023: $389 · 2024: $456 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $711.13 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $434.29 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $204.38 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $183.40 | 2025 | Jornay Pm |
| Kaleo, INC. | $139.53 | 2019-2023 | Auvi-Q |
| Jazz Pharmaceuticals INC. | $131.80 | 2019-2025 | |
| Cranial Technologies, INC | $120.46 | 2019-2023 | Doc Band |
| Phadia US INC. | $115.02 | 2020-2025 | Immunocap |
| Seqirus USA INC | $107.05 | 2021-2025 | Flucelvax |
| Supernus Pharmaceuticals, INC. | $102.97 | 2021-2025 | Qelbree |
| Sobi, INC | $73.37 | 2021-2022 | |
| Sanofi Pasteur INC. | $71.44 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $67.09 | 2023-2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $65.33 | 2022-2023 | Shingrix, Arexvy |
| Pfizer INC. | $59.30 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.67 | 2020-2025 | Enflonsia, Gardasil 9 |
| Alk-Abello, INC | $56.67 | 2025 | Neffy, Ragwitek, Grastek |
| Biogen, INC. | $52.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.26 | 2020-2025 | Elaprase |
| Sanofi-Aventis U.S. LLC | $26.35 | 2024 | |
| Adlon Therapeutics L.P. | $25.46 | 2019 | |
| Exeltis, USA INC. | $22.59 | 2023 | Slynd |
| Neos Therapeutics, LP | $18.11 | 2019 | |
| Mckesson Medical-Surgical, INC. | $15.73 | 2021 | |
| Shire North American Group INC | $15.64 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.29 | 2019 | |
| Novo Nordisk INC | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Butcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.